Otsuka Pharmaceutical's Phase III trial on sibeprenlimab for IgA nephropathy showed positive interim results. The monoclonal antibody demonstrated a significant reduction in urine protein levels, meeting the primary endpoint.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing